today announced that the Company and leading doctors from Johns Hopkins University co-hosted a meeting with prospective medical trial investigators at the recent American Academy of Neurology Annual Interacting with in New Orleans. Johns Hopkins University will serve as the business lead trial site for the study. An interview with Professor Lesley JonesAutoantibody position fails to predict death risk in systemic sclerosis with PAHDiabetic retinopathy therapy improvements: an interview with Richard Kirk, CEO of PolyphotonixA group of invited crucial opinion leaders and neurologists from leading Multiple Sclerosis Centers of Excellence attended the Cyrevia investigators conference, hearing presentations from two Johns Hopkins physicians: Douglas E.These models can be used to discover and validate essential biomarkers which may predict responder versus non-responder profiles, and translational analysis readouts which can be examined in the clinic The pharmaceutical and biotechnology sectors are seeking more relevant and accurate preclinical versions to underpin their medication discovery work. It is likely that a combination of therapies shall be essential to prevent and/or deal with resistant tumours. The amount of therapeutic combinations is vast therefore preclinical models are had a need to correctly identify the proper mixtures for the relevant resistance along with define the individual populations in which they'll be most efficacious. This will involve both in vitro and in vivo platforms, but both have to recapitulate the individual resistant disease as carefully as possible.